<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603642</url>
  </required_header>
  <id_info>
    <org_study_id>20060216</org_study_id>
    <nct_id>NCT00603642</nct_id>
  </id_info>
  <brief_title>P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled Phase 3 Study Evaluating the Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of AMG 531 compared with
      placebo in thrombocytopenic Japanese subjects with immune (idiopathic) thrombocytopenic
      purpura (ITP) .
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weeks With Weekly Platelet Response</measure>
    <time_frame>12 weeks (Weeks 2 - 13)</time_frame>
    <description>Number of weeks with weekly platelet response. A weekly platelet response is defined as a platelet count of ≥ 50 x 10^9/L on a weekly scheduled dose day from week 2 to week 13.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increased Platelet Count From Baseline of at Least 20 x 10^9/L</measure>
    <time_frame>Baseline, 12 weeks (Weeks 2 - 13)</time_frame>
    <description>An increase in platelet count of at least 20 x 10^9/L from baseline within the participant during the treatment period. Increase was calculated as the maximum observed platelet count during the treatment period minus the baseline platelet count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean of Last 4 Weekly Platelet Counts</measure>
    <time_frame>12 weeks (Weeks 2 - 13)</time_frame>
    <description>Change from baseline in the mean of the last 4 weekly platelet counts from week 2 to week 13.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weeks With Platelet Count Between 50 and 200</measure>
    <time_frame>12 weeks (Weeks 2 - 13)</time_frame>
    <description>Number of weeks with platelet count between 50 x 10^9/L and 200 x 10^9/L inclusive during week 2 to week 13.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication(s)</measure>
    <time_frame>12 weeks (Weeks 2 - 13)</time_frame>
    <description>Requirement for rescue medication(s) during treatment by the participant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Idiopathic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>AMG 531</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double blinded placebo-controlled study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneously administered, once a week, for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 531</intervention_name>
    <description>Subcutaneously administered, once a week, for 12 weeks</description>
    <arm_group_label>AMG 531</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese patients with diagnosis of ITP according to the diagnostic criteria proposed
             by Research Committee for Idiopathic Hematopoietic Disorders of the Ministry of
             Health, Labour and Welfare [MHLW] (revised in 1990) at least 6 months before the first
             screening visit

          -  The mean of the 3 scheduled platelet counts taken at the scheduled visits during the
             screening period must be ≤ 30 x 10^9/L, with no individual count &gt; 35 x 10^9/L

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  Subjects must be ≥ 20 years of age at the time of obtaining the informed consent

          -  Have received at least 1 prior treatment for ITP

          -  If known Helicobacter pylori positive, having completed one course of Helicobacter
             pylori eradication therapy at least 12 weeks before the first screening visit

          -  A hemoglobin value taken at scheduled visit during the screening period must be ≥ 10
             g/dL

          -  A serum creatinine concentration taken at scheduled visit during the screening period
             must be ≤ 2 mg/dL

          -  Adequate liver function, as evidenced by a total bilirubin taken at scheduled visit
             during the screening period ≤ 1.5 times of the upper limit of the normal range (except
             for patients with a confirmed diagnosis of Gilbert's Disease) or an alanine
             aminotransferase and aspartate aminotransferase taken at the screening visit ≤ 3 times
             of the upper limit of the normal range

        Exclusion Criteria:

          -  Any known history of bone marrow stem cell disorder. Any abnormal bone marrow findings
             other than those typical of ITP.

          -  Any active malignancy. If prior history of cancer other than basal cell carcinoma or
             cervical carcinoma in situ, no treatment or active disease within 5 years before the
             first screening visit.

          -  Documented diagnosis of arterial thrombosis (eg, stroke, transient ischemic attack, or
             myocardial infarction); history of venous thrombosis (eg, deep vein thrombosis,
             pulmonary embolism) and receiving anticoagulation therapy at the first screening
             visit.

          -  Documented diagnosis of anti phospholipid antibody syndrome

          -  Currently receiving any treatment for ITP except oral corticosteroids, azathioprine
             and/or danazol administered at a constant dose and schedule from at least 4 weeks
             prior to the first screening visit

          -  Received intravenous immunoglobulin, anti D immunoglobulin, or any drug administered
             to increase platelet counts (eg, immunosuppressants except azathioprine) within 2
             weeks before the first screening visit

          -  Have had a splenectomy for any reason within 12 weeks before the first screening visit

          -  Past or present participation in any study evaluating pegacaristim (polyethylene
             glycol-conjugated recombinant human megakaryocyte growth and development factor,
             KRN9000), Eltrombopag (SB 497115), recombinant human thrombopoietin, AMG 531, or other
             Mpl stimulation product

          -  Received hematopoietic growth factors (eg, granulocyte colony stimulating factor,
             macrophage colony stimulating factor, erythropoietin, interleukin 11) for any reason
             within 4 weeks before the first screening visit

          -  Received any anti malignancy agents (eg, cyclophosphamide, 6 mercaptopurine,
             vincristine, vinblastine, Interferon alfa) for any reason within 8 weeks before the
             first screening visit

          -  Received any monoclonal antibody drugs (eg, rituximab) for any reason within 14 weeks
             before the first screening visit

          -  Less than 4 weeks since receipt of any therapeutic drug or device that is not MHLW
             approved for any indication before the first screening visit

          -  Pregnant or breast feeding

          -  Subjects of reproductive potential who are not using adequate contraceptive
             precautions, in the judgment of the investigator

          -  Known severe drug hypersensitivity

          -  Concerns for subject's compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2008</study_first_submitted>
  <study_first_submitted_qc>January 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2008</study_first_posted>
  <results_first_submitted>November 18, 2010</results_first_submitted>
  <results_first_submitted_qc>November 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 10, 2010</results_first_posted>
  <last_update_submitted>February 4, 2011</last_update_submitted>
  <last_update_submitted_qc>February 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>AMG 531</keyword>
  <keyword>Idiopathic Thrombocytopenic Purpura</keyword>
  <keyword>ITP</keyword>
  <keyword>Thrombocytopenia</keyword>
  <keyword>Japan</keyword>
  <keyword>Placebo controlled</keyword>
  <keyword>Phase 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 20 November 2007 through 11 December 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo administered subcutaneously once weekly for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Romiplostim</title>
          <description>Romiplostim administered subcutaneously once weekly for 12 weeks at a starting dose of 3 µg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo administered subcutaneously once weekly for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Romiplostim</title>
          <description>Romiplostim administered subcutaneously once weekly for 12 weeks at a starting dose of 3 µg/kg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.6" spread="13.4"/>
                    <measurement group_id="B2" value="58.5" spread="12.6"/>
                    <measurement group_id="B3" value="54.7" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelet Count</title>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.8" spread="8.6"/>
                    <measurement group_id="B2" value="18.4" spread="8.3"/>
                    <measurement group_id="B3" value="17.5" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Weeks With Weekly Platelet Response</title>
        <description>Number of weeks with weekly platelet response. A weekly platelet response is defined as a platelet count of ≥ 50 x 10^9/L on a weekly scheduled dose day from week 2 to week 13.</description>
        <time_frame>12 weeks (Weeks 2 - 13)</time_frame>
        <population>Full Analysis Set, composed of all randomized participants who received at least 1 dose of romiplostim or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously once weekly for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Romiplostim</title>
            <description>Romiplostim administered subcutaneously once weekly for 12 weeks at a starting dose of 3 µg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Weeks With Weekly Platelet Response</title>
          <description>Number of weeks with weekly platelet response. A weekly platelet response is defined as a platelet count of ≥ 50 x 10^9/L on a weekly scheduled dose day from week 2 to week 13.</description>
          <population>Full Analysis Set, composed of all randomized participants who received at least 1 dose of romiplostim or placebo</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="11.0" lower_limit="9.0" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increased Platelet Count From Baseline of at Least 20 x 10^9/L</title>
        <description>An increase in platelet count of at least 20 x 10^9/L from baseline within the participant during the treatment period. Increase was calculated as the maximum observed platelet count during the treatment period minus the baseline platelet count.</description>
        <time_frame>Baseline, 12 weeks (Weeks 2 - 13)</time_frame>
        <population>Full Analysis Set, composed of all randomized participants who received at least 1 dose of romiplostim or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously once weekly for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Romiplostim</title>
            <description>Romiplostim administered subcutaneously once weekly for 12 weeks at a starting dose of 3 µg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Increased Platelet Count From Baseline of at Least 20 x 10^9/L</title>
          <description>An increase in platelet count of at least 20 x 10^9/L from baseline within the participant during the treatment period. Increase was calculated as the maximum observed platelet count during the treatment period minus the baseline platelet count.</description>
          <population>Full Analysis Set, composed of all randomized participants who received at least 1 dose of romiplostim or placebo</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean of Last 4 Weekly Platelet Counts</title>
        <description>Change from baseline in the mean of the last 4 weekly platelet counts from week 2 to week 13.</description>
        <time_frame>12 weeks (Weeks 2 - 13)</time_frame>
        <population>Full Analysis Set, composed of all randomized participants who received at least 1 dose of romiplostim or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously once weekly for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Romiplostim</title>
            <description>Romiplostim administered subcutaneously once weekly for 12 weeks at a starting dose of 3 µg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean of Last 4 Weekly Platelet Counts</title>
          <description>Change from baseline in the mean of the last 4 weekly platelet counts from week 2 to week 13.</description>
          <population>Full Analysis Set, composed of all randomized participants who received at least 1 dose of romiplostim or placebo</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="6.5"/>
                    <measurement group_id="O2" value="109.7" spread="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weeks With Platelet Count Between 50 and 200</title>
        <description>Number of weeks with platelet count between 50 x 10^9/L and 200 x 10^9/L inclusive during week 2 to week 13.</description>
        <time_frame>12 weeks (Weeks 2 - 13)</time_frame>
        <population>Full Analysis Set, composed of all randomized participants who received at least 1 dose of romiplostim or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously once weekly for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Romiplostim</title>
            <description>Romiplostim administered subcutaneously once weekly for 12 weeks at a starting dose of 3 µg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Weeks With Platelet Count Between 50 and 200</title>
          <description>Number of weeks with platelet count between 50 x 10^9/L and 200 x 10^9/L inclusive during week 2 to week 13.</description>
          <population>Full Analysis Set, composed of all randomized participants who received at least 1 dose of romiplostim or placebo</population>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.4"/>
                    <measurement group_id="O2" value="6.3" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Medication(s)</title>
        <description>Requirement for rescue medication(s) during treatment by the participant</description>
        <time_frame>12 weeks (Weeks 2 - 13)</time_frame>
        <population>Full Analysis Set, composed of all randomized participants who received at least 1 dose of romiplostim or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously once weekly for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Romiplostim</title>
            <description>Romiplostim administered subcutaneously once weekly for 12 weeks at a starting dose of 3 µg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Medication(s)</title>
          <description>Requirement for rescue medication(s) during treatment by the participant</description>
          <population>Full Analysis Set, composed of all randomized participants who received at least 1 dose of romiplostim or placebo</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6015</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks of treatment plus follow-up period up to 12 weeks</time_frame>
      <desc>The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Romiplostim</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid function disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>IIIrd nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrocalcinosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Polymenorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

